Home>Topics>Stocks>Alexza Pharmaceuticals

Alexza Pharmaceuticals ALXA

  1. All
  2. Commentary
  3. Headlines
    1. Alexza raises $45M

      Headlines

      Wed, 19 Mar 2014

      Alexza Pharmaceuticals ( ALXA ) closes $45M non-recourse notes in a private placement. Interest rate is 12.25%/year beginning June 15. Debt secured

    2. Alexza Pharmaceuticals Management Discusses Q4 2013 Results - Earnings Call Transcript

      Headlines

      Thu, 6 Mar 2014

      Alexza Pharmaceuticals ( ALXA ) Q4 2013 Earnings Call March 06, 2014 5:00 pm ET Executives ..... Presentation Operator Good afternoon, everyone, and welcome to the Alexza Pharmaceuticals 2014 Fourth Quarter and Yearend Financial Results Conference

    3. Alexza Pharmaceuticals , Inc. beats by $0.43, beats on revenue

      Headlines

      Thu, 6 Mar 2014

      Alexza Pharmaceuticals , Inc. ( ALXA ): Q4 EPS of -$0.33 beats by $0.43 . Revenue of $1.3M beats by $0.18M . Press Release Post your comment!

    4. Alexza resubmits drug application early, shares soar

      Headlines

      Fri, 22 Jun 2012

      (Reuters) - Alexza Pharmaceuticals Inc resubmitted the marketing application for its anti-agitation treatment earlier than expected, sending its shares up as much as 47 percent.

    5. Setback for Valeant's Drug Candidate Adusuve Staccato

      Commentary

      Mon, 11 Oct 2010

      Valeant Pharmaceuticals VRX announced Monday that its partner Alexza Pharmaceuticals ALXA received a complete response letter on drug candidate adusuve staccato (formerly known as staccato loxapine). We will maintain

    6. Dropping Coverage of Alexza

      Commentary

      Mon, 7 Sep 2009

      We are no longer providing equity research on Alexza Pharmaceuticals ALXA . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    7. Alexza to Acquire Longtime Partner

      Commentary

      Tue, 16 Jun 2009

      Alexza Pharmaceuticals ALXA announced that it has exercised its option to purchase longtime partner Symphony Allegro in a deal expected to close in the third

    8. Cash Still a Concern for Alexza

      Commentary

      Fri, 8 May 2009

      Despite Alexza Pharmaceuticals ' ALXA success at narrowing its net loss for the first quarter, we are keeping our fair value estimate in place because of our continuing

    9. Alexza under Review

      Commentary

      Fri, 30 Jan 2009

      We are putting Alexza Pharmaceuticals ALXA under review after the firm announced that it will reduce its workforce by 33% and halt certain early-stage drug-development

    10. Positive Phase III Data for Alexza

      Commentary

      Wed, 10 Dec 2008

      Alexza Pharmaceuticals ALXA announced positive results from its second Phase III trial of its lead antipsychotic drug, AZ-004, for treatment of acute agitation

    « Prev12Next »
    Content Partners